March 17, 2016—The chairwoman of the Senate Special Committee on Aging excoriated a Turing Pharmaceuticals executive during a hearing today for instructing a subordinate to dispute 340B claims in order to boost company profits. … [Read more...]
340B Hospitals Criticize MedPAC’s Plan to Cut Their Medicare Drug Reimbursement
Commission's ideas would radically restructure drug discount programMarch 16, 2016—Safety-net hospitals are criticizing a Medicare advisory panel's recommendation that Congress should reduce Medicare payment rates for 340B hospitals’ separately payable 340B drugs by 10 percent of the average sales price (ASP), redirect the money saved to the Medicare-funded uncompensated care pool, and distribute those funds using data from the Medicare cost … [Read more...]
Delaware Bars Using 340B Drugs for Medicaid Beneficiaries
Says rule will simplify obtaining rebates and eliminate an area for provider auditsMarch 15, 2016—Delaware Medicaid has adopted a rule, subject to federal Centers for Medicare & Medicaid Services approval, barring healthcare providers from using 340B-purchased drugs for managed-care and fee-for-service Medicaid beneficiaries. … [Read more...]
HHS: Price Hikes, Specialty Drugs Driving Up Drug Spending
Total spending expected to exceed half a trillion dollars in 2018March 10, 2016—U.S. prescription drug spending is climbing steeply and projected to keep rising as a share of total healthcare spending, the U.S. Department of Health and Human Services says in a new report. … [Read more...]
HRSA Says Drugmakers Can Give 340B Orphan Drug Discounts Voluntarily
Updates website language about October 2015 court rulingMarch 7, 2016—Although drugmakers are not required to provide rural and cancer hospitals 340B discounts on orphan drugs, they may do so voluntarily, the Health Resources and Services Administration says in an update to the Office of Pharmacy Affairs website. … [Read more...]
Trump Fleshes Out Healthcare Policies
Although drug industry "is in the private sector…[it] provide[s] a public service"March 3, 2016—Republican presidential candidate Donald Trump has fleshed out his healthcare agenda in a seven-point position paper that includes repealing the Affordable Care Act, giving states more control over Medicaid, and removing barriers to drug imports. … [Read more...]
Brand-name and Specialty Drug Prices Skyrocketing, AARP Study Finds
Nation might not be able to rely on lower-priced generics as a counterbalance any longerMarch 1, 2016—Retail prices for 622 brand name, generic, and specialty prescription drugs widely used by Medicare beneficiaries rose by an average of 9.4 percent in 2013, a far higher rate than in the previous seven years and far above 2013's general inflation rate of 1.5 percent, new research shows. … [Read more...]